Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases

NCT05081921 | Completed Phase 1 DMC

• 2 other identifiers: JU-BioMiStem-012019-005000-17
• Study Type: interventional
• Target: 192
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to evaluate safety, tolerability and clinical efficacy of a newly developed MesoCellA-Ortho tissue-engineered advanced therapy medicinal product in adult patients suffering with osteoarthritis and additionally burdened with other civilisation diseases such as type 2 diabetes and/ or obesity. The active substance of MesoCellA-Ortho consists of in vitro expanded autologous human adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) resuspended in carrier solution for intraarticular injections for individual patents.

Conditions

Osteoarthritis of Knee

Keywords

Osteoarthritis; Mesenchymal stem cells; Autologous stem cells; Adipose tissue; Type 2 diabetes; Obesity; Civilisation diseases

Outcome Measures

Primary Outcomes (6)

• Nature, incidence and severity of adverse events (AEs)

  The measure of safety used in this study are routine clinical procedures. They include a close vigilance for, and stringent reporting of selected local and systemic reactions, adverse events including serious adverse events. After 4th rehabilitation visit to study termination, only AEs of special interest and serious adverse events (SAEs), AEs leading to withdrawal from the study and concomitant medications used to treat adverse events will be collected. The AEs of special interest related directly to the state of the knee after intraarticular administration will be: excessive warming of the knee, pain, suffusion, hematoma, knee locking, decrease ROM. The prevalence, duration and severity of AEs of special interest will be additionally analyzed in the study.

  Month 6 Follow-up

• Change in Numerical Rating Scale (NRS)

  The numerical scale is one of the most commonly used pain scales in medicine. The NRS consists of a numeric version of the visual analog scale. It is labeled from 0 to 10, with 0 being "no pain" and 10 being "the worst pain imaginable". This scale can help guide the diagnostic process, track the progression of the pain, and more. Patients will report intensity of pain only in knee subjected to the treatment in the study.

  Month 3 and Month 6 Follow-up

• Change in joint swelling

  Evaluation the joint swelling during physical examination by 4-items scale: none, mild, moderate, severe. Joint swelling will be assessed only knee subjected to the treatment in the study.

  Month 3 and Month 6 Follow-up

• Change in the 36-Item Short Form Survey (SF-36)

  SF-36 is an oft-used, well-researched, self-reported measure of health. The SF-36 is often used as a measure of a person or population's quality of life. It comprises 36 questions which cover eight domains of health: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); 8) general health perceptions.

  Month 6 Follow-up

• Change in Knee injury and Osteoarthritis Outcome Score (KOOS)

  Change in Knee injury and Osteoarthritis Outcome Score (KOOS). It holds 42 items in 5 separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL) The five patient-relevant subscales of KOOS are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic assessment scales and generic measures. Only knee subjected to treatment will be evaluated by KOOS survey.

  Month 3 and Month 6 Follow-up

• Change in the International Knee Documentation Committee (IKDC 2000)

  Change in IKDC Questionnaire score. The questionnaire looks at 3 categories: symptoms, sports activity, and knee function. The symptoms subscale helps to evaluate things such as pain, stiffness, swelling and giving-way of the knee. Scores are obtained by summing the individual items, then transforming the crude total to a scaled number that ranges from 0 to 100. This final number is interpreted as a measure of function with higher scores representing higher levels of function The transformed score is interpreted as a measure of function such that higher scores represent higher levels of function and lower levels of symptoms. A score of 100 is interpreted to mean no limitation with activities of daily living or sports activities and the absence of symptoms. Only knee subjected to treatment will be evaluated by IKDC 2000 survey.

  Month 3 and Month 6 Follow-up

Secondary Outcomes (6)

• Change in cartilage morphology

  Month 6 Follow-up

• Change in cartilage T2 relaxation time mapping in MRI

  Month 6 Follow-up

• Changes in bone marrow edema-like lesions (BMLs)

  Month 6 Follow-up

• Change in weight distribution on stable platform

  Month 6 Follow-up

• Change in Range of motion (ROM)

  Month 6 Follow-up

Study Arms (6)

MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity

EXPERIMENTAL

The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI \> 30) will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)

Drug: MesoCellA-Ortho administration

Control Patients with type 2 diabetes and obesity

ACTIVE COMPARATOR

The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI \> 30) will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)

Drug: HA administration

MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity

EXPERIMENTAL

The patients with osteoarthritis of knee, suffering also with obesity (BMI \> 30), but with no type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)

Drug: MesoCellA-Ortho administration

Control Patients without type 2 diabetes and with obesity

ACTIVE COMPARATOR

The patients with osteoarthritis of knee, suffering also with obesity (BMI \> 30), but with no type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)

Drug: HA administration

MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity

EXPERIMENTAL

The patients with osteoarthritis of knee, with no obesity (BMI \< 30) nor type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)

Drug: MesoCellA-Ortho administration

Control Patients without type 2 diabetes and without obesity

ACTIVE COMPARATOR

The patients with osteoarthritis of knee, with no obesity (BMI \< 30) nor type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)

Drug: HA administration

Interventions

MesoCellA-Ortho administration DRUG

Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in "MesoCellA-Ortho- treated" groups.

Also known as: Experimental treatment

MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity; MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity; MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity

HA administration DRUG

Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in "Control Patients" groups.

Also known as: Standard treatment (control)

Control Patients with type 2 diabetes and obesity; Control Patients without type 2 diabetes and with obesity; Control Patients without type 2 diabetes and without obesity

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Knee cartilage lesions (osteoarthritis II/III grade in Kellgren-Lawrence scale confirmed in X-ray)
• Age between 40-70 years (inclusive)
• No contraindications for liposuction
• No contraindications for the general use of biological treatment, stem cells, PRP and whole autologous blood
• Availability to take part into all study visits, barring unforeseen circumstances
• Able and willing to perform exercises at home given by a physiotherapist
• Contraceptive (birth control pills, injection, pessary or intrauterine device (IUD), spermicide condoms)
• The pain intensity in treated knee not lower than grade 3 (on 11-point Numerical Rating Scale)

You may not qualify if:

• A history of cancer for 2 years before screening. In case of history of cancer medical above 2 years, consultation with oncologist and her/his permission for participation in clinical trial will be obligatory.
• Pregnant or breastfeeding women.
• Allergy or poor tolerance of hyaluronic acid.
• Diabetes mellitus type 1, diabetes mellitus type 2 on insulin treatment.
• Lack of medical consultation in case of patients with diabetes group.
• Comorbidities significantly affecting overall health (e.g. history of myocardial infarction, heart failure, thrombophlebitis, arterial hypertension (hypertensive crises), chronic obstructive pulmonary disease, renal failure, liver failure, advanced atherosclerosis, psychoorganic syndrome, hemiparesis, history of stroke).
• Current or medical history of the patient: inflammatory diseases of the joints (e.g. gout, reactive arthritis, psoriatic arthritis, seronegative arthritis involving the spine joints, septic arthritis, prior diagnosis of target arthrosis with crystal precipitation or elevated CRP in the condition, inflammation), osteonecrosis, osteoporotic fractures or other painful joint diseases other than osteoarthritis; secondary causes of osteoarthritis (e.g. rheumatoid arthritis, fibromyalgia, birth defects).
• Current or medical history of the patient concerning carrier state or diseases: HIV, syphilis, HBV, HCV, EBV.
• Symptomatic sciatica with radiation of pain to the examined limb.
• Symptomatic osteoarthritis of the hip of both limbs.
• Significant knee injuries within 6 months such as: ligament injuries, distal femur fracture or proximal tibia fracture, arthrofibrosis or cyclops lesions.
• Endoprosthesis of the hip or knee joints.
• Partial / total knee or hip joints replacement planned during the study.
• Surgical operation of the lower limbs (including arthroscopy) within 6 months before screening visit or planned during the study.
• Constant use of orthopaedic aids.

Sponsors & Collaborators

• Jagiellonian University: lead
• National Center for Research and Development, Poland: collaborator
• KCRI: collaborator

Study Sites (1)

Galen - Ortopedia Sp. Z O.O.

Bieruń, Silesian Voivodeship, 43-150, Poland

Location

MeSH Terms

Conditions

Osteoarthritis, Knee; Osteoarthritis; Diabetes Mellitus, Type 2; Obesity

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Krzysztof Ficek, Prof., MD, PhD, DSc

  Galen Ortopedia Sp. z o. o

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: A randomization list and envelope based procedure will be used to eliminate selection bias. In order to maximally reduce bias, the trial is double-blind, with all involved subjects and the investigator blinded to the treatment. The randomization list will not be available to any person involved in the conduct. The evaluation of the trial results will not be performed until the trial database is locked.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Randomized

Study Record Dates

• First Submitted: August 23, 2021
• First Posted: October 18, 2021
• Study Start: January 5, 2022
• Primary Completion: February 20, 2024
• Study Completion: February 20, 2024
• Last Updated: March 21, 2024

Record last verified: 2024-03

Locations

PL (1)